Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 1003-1011

  Scagnolari, Carolina ^a   Vicenzi, Elisa ^b   Bellomi, Francesca ^a   Stillitano, Maria Giuseppina ^a   Pinna, Debora ^b   Poli, Guido ^b,c   Clementi, Massimo ^b,c   Dianzani, Ferdinando ^d   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOSENSITIVITY; COMPARATIVE STUDY; DRUG POTENTIATION; ENCEPHALOMYOCARDITIS VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SARS CORONAVIRUS; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DRUG SYNERGISM; GTP-BINDING PROTEINS; HUMANS; INTERFERON TYPE I; INTERFERON TYPE II; RECOMBINANT PROTEINS; SARS VIRUS; VERO CELLS; VIRUS REPLICATION;

EID: 11144300137     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Drosten C, Gunther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H & Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England Journal of Medicine 2003; 348:1967-1976.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, Derisi J, Yang JY, Cox N, Hughes JM, Leduc JW, Bellini WJ & Anderson LJ. A novel coronavirus associated with severe acute respiratory syndrome. New England Journal of Medicine 2003; 348:1953-1966.
3. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, Van Amerongen G, Van Riel D, Laman JD, De Jong T, Van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, Van Der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS & Osterhaus AD. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362:263-270.
4. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY & SARS Study Group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-1325.
5. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, Derisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, Mccaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ & Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-1399.
6. Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, Bordignon C, Poli G & Clementi M. Coronaviridae features and SARS-associated coronavirus Strain HSR1. Emerging Infectious Diseases 2004; 10:413-418.
7. Samuel CE. Antiviral actions of interferons. Clinical Microbiology Reviews 2001; 14:778-809.
8. Goodbourn S, Didcock L & Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 2000; 81:2341-2364.
9. Reed LJ & Muench H. A simple method of estimating fifty percent endpoints. American Journal of Hygiene 1938; 27:493-497.
10. Chou TC & Talalay YP. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
11. Sen GC. Novel functions of interferon-induced proteins. Seminars in Cancer Biology 2000; 10:93-101.
12. Haller O & Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002; 3:710-717.
13. Crespi M, Chiu MN, Struthers JK, Schoub BD & Lyons SF. Effect of interferon on Vero cells persistently infected with Sendai virus compared to Vero cells persistently infected with SSPE virus. Archives of Virology 1988; 98:235-251.
14. Paez E, Garcia F & Gil Fernandez C. Interferon cures cells lytically and persistently infected with African swine fever virus in vitro. Archives of Virology 1990; 112:115-127.
15. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H & Doerr HW. Treatment of SARS with human interferons. Lancet 2003; 362:293-294.
16. Hensley LE, Fritz EA, Jahrling PB, Karp C, Huggins JW & Geisbert TW, Interferon-β la and SARS coronavirus replication. Emerging Infectious Diseases 2004; 10:317-319.
17. Stroher U, Dicaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM & Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. Journal of Infectious Diseases 2004; 189:1164-1167.
18. Chen F, Chan KH, Yiang Y, Kao RYT, Lu HAT, Fan KW, Cheng VCC, Tsui WHW, Hung IFN, Lee TSW, Guan Y, Peiris JSM & Yuen KY. In vitro susceptibility of 10 isolates of SARS coronavirus to selected antiviral compounds. Journal of Clinical Virology 2004; 31:69-75.
19. Zheng B, He ML, Wong KL, Lum CT, Poon LLM, Peng Y, Guan Y, Lin MCM & Kung HF. Potent inhibition of SARS-associated coronavirus (ScoV) infection and replication by type I interferons (IFN-α/β) but not by type II interferon (IFN-γ). Journal of Interferon & Cytokine Research 2004; 24:388-390.
20. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Van Riel D, De Jong T, Itamura S, Chan KH, Tashiro M & Osterhaus AD. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Medicine 2004; 10:290-293.
21. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, Lamere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK & Fish EN. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Journal of the American Medical Association 2003; 290:3222-3228.
22. Yamamoto S, Yano H, Sanou O, Ikegami H, Kurimoto M & Kojiro M. Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8. Hepatology Research 2002; 24:99.
23. Spiegel M, Pichlmair A, Muhlberger E, Haller O & Friedemann WJ. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. Journal of Clinical Virology 2004; 30:211-213.
24. Fleischmann WR Jr. Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence. Cancer Research 1982; 42:869-875.
25. Czarniecki CW, Fennie CW, Powers DB & Estell DA. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. Journal of Virology 1984; 49:490-496.
26. Schwarz LA, Fleischmann CM & Fleischmann WR Jr. Potentiation of interferon's antiviral activity by the mutually synergistic interaction of MuIFN-alpha/beta and MuIFN-gamma. Journal of Biological Response Modifiers 1984; 3:608-612.
27. Gomi K, Kimura H, Okabe M, Oka T & Morimoto M. Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta. Journal of Journal of Pharmacobio-dynamics 1986; 9:871-878.
28. Sim IS & Cerruti RL. Recombinant interferons alpha and gamma: comparative antiviral activity and synergistic interaction in encephalomyocarditis virus infection of mice. Antiviral Research 1987; 8:209-221.
29. Lewis JA, Huq A & Shan B. Beta and gamma interferons act synergistically to produce an antiviral state in cells resistant to both interferons individually. Journal of Virology 1989; 63:4569-4578.
30. Sekellick MJ, Lowenthal JW, O'Neil TE & Marcus PI. Chicken Interferon types I and II enhance synergistically the antiviral state ana nitric oxide secretion. Journal of Interferon & Cytokine Research 1998; 18:407-414.
31. Sainz B Jr & Halford WP. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. Journal of Virology 2002; 76:11541-11550.
32. Fuchizaki U, Kaneko S, Nakamoto Y, Sugiyama Y, Imagavva K, Kikuchi M & Kobayashi K. Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus. Journal of Medical Virology 2003; 69:188-194.
33. Levy DE, Lew DJ, Decker T, Kessler DS & Darnell JE Jr. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO Journal 1990; 9:1105-1111.
34. Mizukoshi E, Kaneko S, Yanagi M, Ohno H, Matsushita E & Kobayashi K. Upregulation of type I interferon receptor by IFN-gamma. Journal of Interferon & Cytokine Research 1999; 19:1019-1023.
35. Kato Y, Noda Y, Unoura M, Tanaka N, Kobayashi K, Hattori N, Hatano K & Kobayashi S. Effect of exogenous mouse interferon on murine fulminant hepatitis induced by mouse hepatitis virus type 2. Digestive Diseases & Sciences 1986; 31:7780.
36. Minagawa H, Takenaka A, Mohri S & Mori R. Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection. Antiviral Research 1987; 8:85-95.
37. Sperber SJ & Hayden FG. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. Journal of Interferon Research 1989; 9:285-293.
38. Pei J, Sekellick MJ, Marcus PI, Choi IS & Collisson EW. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. Journal of Interferon & Cytokine Research 2001; 21:1071-1077.